Topics:
Lung Cancer • Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Non-small cell lung cancer • Vanderbilt
When do you recommend broader molecular testing for clinical trials in stage IV NSCLC patients who have negative initial molecular testing for FDA-approved targetable mutations?
Answer from: Medical Oncologist at Academic Institution
This is an important question, and it depends on a few patient and test characteristics. In a younger patient or a never smoker I would advise broader genomic testing at diagnosis. In an older patients or current/prior moderate to heavy smokers I would advise re-biopsy at the time of progre...
Sign in or Register to read more